
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Aldolase A CRISPR/Cas9 KO Plasmid (m) | sc-419082 | 20 µg | $397.00 |
Aldoa encodes aldolase A, a glycolytic enzyme that catalyzes the reversible cleavage of fructose-1,6-bisphosphate into glyceraldehyde-3-phosphate and dihydroxyacetone phosphate, linking glucose utilization to ATP production and biosynthetic precursor generation. In mouse cells, aldolase A supports metabolic flux through glycolysis and interfaces with broader carbon metabolism programs that influence redox balance and cellular proliferation. Beyond metabolism, aldolase A has been implicated in cytoskeletal organization through interactions with actin dynamics, connecting energy production with cell shape and motility. Altered ALDOA expression and glycolytic rewiring are frequently studied in contexts of metabolic stress and disease-associated phenotypes, including tumor-associated metabolic adaptation and muscle-related functional deficits.
Aldolase A CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Aldoa gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Aldoa together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Aldoa open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Aldolase A protein expression.
This CRISPR knockout system enables efficient generation of Aldoa-deficient cell models for investigation of Aldolase A signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.